Qilu Pharmaceutical Group

Qilu PharmaceuticalQilu Pharmaceutical operates across three strategic segments - human health, plant protection, and animal health - supported by six R&D hubs in China and U.S., focusing on major therapeutic areas, including oncology, immunology, ophthalmology, diabetes, etc. With 11 manufacturing sites, 12 subsidiaries, and over 39,000 employees, Qilu recorded USD 5.48 billion in sales revenue in 2025, including USD 1.11 billion from exports. Qilu was the first Chinese company certified for sterile products by the U.S., EU, and UK, with an end-to-end quality system aligned with international standards. In China, it has launched over 350 products - 88 of them first-to-market or exclusive - with 72 finished formulations and 13 APIs leading their markets, spanning 4 innovative drugs, 24 high-barrier complex formulations, and 16 blockbuster biologics. Internationally, 119 finished products have been exported to over 110 countries and regions. For many years, Qilu has remained the only Chinese company exporting finished formulations simultaneously to EU, U.S., UK, Japan, Australia, and Canada, with 40 products ranking first locally and 12 human-use APIs (including the cephalosporin series and the β-lactamase inhibitor series) leading globally.